Two New Sesquiterpenes from Ligularia Duciformis

ＡｐｒｅｖｉｏｕｓｐｈｙｔｏｃｈｅｍｉｃａｌｓｔｕｄｙｏｆＬｉｇｕｌａｒｉａｄｕｃｉｆｏｒｍｉｓｄｅａｌｔｗｉｔｈｔｈｅｉｓｏｌａｔｉｏｎｏｆｃｏｎｉｆｅｒｙｌａｌｃｏｈｏｌｄｅｒｉｖａｔｉｖｅｓ［１,２］．Ｉｎｏｒｄｅｒｔｏｆｉｎｄｓｅｓｑｕｉｔｅ...     

Syntheses of TiO2(B) nanowires and TiO2 anatase nanowires by hydrothermal and post-heat treatments

TiO₂(B) nanowires and TiO₂ anatase nanowires were synthesized by the hydrothermal processing in 10 M NaOH aq. at 150 °C followed by the post-heat treatment at 300-800 °C. As-synthesized Na-free titanate nanowires (prepared by the hydrothermal treatment and repeated ion exchanging by HCl (aq.) were transformed into TiO₂(B) structure with maintaining 1-D morphology at 300-500 °C, and further transformed into anatase structure at 600-800 °C with keeping 1-D shape. At 900 °C, they transformed into rod-shaped rutile grains. Microstructure of these 1-D TiO₂ nanomaterials is reported.     

超细Pd—B／SiO2非晶态合金加氢反应的催化活性

采用浸渍法并通过ＫＢＨ４还原制备超细Ｐｄ－Ｂ／ＳｉＯ２非晶态合金催化剂,以硝基苯加氢生成苯胺为目标反应,考察了上述催化剂的活性和选择性及热稳定性,并与晶态Ｐｄ－Ｂ／ＳｉＯ２和Ｐｄ／ＳｉＯ２催化剂及非负载型Ｐｄ－Ｂ非晶态合金催化剂进行了比较。     

银袋内酯乙的乙酰化物的晶体结构和分子结构

本文报道从变色马兜铃(Aristolochia versicolar)的块根中提取的一种新倍半萜内酯-银袋内酯乙的乙酰化物的晶体结构和分子结构.分子式为C~17H~22O~4,分子量290.4,晶体属单斜晶系,空间群为P2~1,a=0.9594(5),b=0.6626(6),c=1.2924(12)um,β=94.48(6)`,V=0.819(1)nm^3,Z=2,Dx=1,18g.cm^-^3,F(000)=266e,μ=0.77cm^-^1(MoKa).结构用直接法解出,经最小二乘法修正后1280个衍射点偏离因子为R=5.5%,Rw=5.2%.分子由椅型.椅型的1,5二烯十员环([2323]矩形)和共用两个相邻DunitzIII型碳C(4),C(5),一个Dunitz II型碳C(6)的五员内酯环组成.十员环与五员内酯环之间夹角为99.该分子骨架拓扑在迄今已知的倍半萜内酯中只与银袋内酯丙相似.所有非氢原子的键长和键角均在实验误差范围内接近理论值。     

HCN消除反应机理的理论研究

采用密度泛函理论方法从HCN氧化和水解两个方面研究了HCN消除反应机理,并考虑了HCN的直接消除反应(途径Ⅰ和途径Ⅱ)和CuO上的HCN消除反应(途径Ⅲ和途径Ⅳ)。途径Ⅰ为HCN与2个O2分子生成CO2、NO和H原子;途径Ⅱ为HCN与1个O2分子和1个H2O分子生成 CO2和NH3;途径Ⅲ为CuO上HNCO水解为CO2和NH3;途径Ⅳ为CuO上HCN水解为CO和NH3。研究发现,途径III速控步骤的活化自由能垒为157.32 kJ/mol,比途径Ⅱ中HNCO水解降低12.34 kJ/mol;比途径Ⅳ降低了63.8 kJ/mol。可见,HNCO是HCN净化过程中的重要中间体,CuO的加入降低了反应能垒,促进了HCN消除。     

Identification of metabolites of Ginkgolide B in vivo and in vitro using ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry

Ginkgolide B is a dietary diterpene with multiple pharmacological activities. However, current research on ginkgolide B is not comprehensive. The current study analyzed the metabolic profile of ginkgolide B in vivo and in vitro using ultra-high-performance liquid chromatography quadrupole time-of-flight mass spectrometry. To detect and identify the different metabolites in ginkgolide B, a novel data processing method was used as an assistant tool. A total of 53 different metabolites of ginkgolide B (38 phase I metabolites and 15 phase II metabolites) were detected relative to blank samples. The biotransformation route of ginkgolide B was identified as oxidation, dehydroxylation, hydrogenation, decarbonylation, demethylation, sulfate conjugation, glucose conjugation, methylation, and acetylation. The current study demonstrated a method for rapidly detecting and identifying metabolites and provided useful information to further characterize the pharmacology and mechanism of ginkgolide B. A method for the analysis of other diterpene metabolic components in vivo and in vitro was also established.     

Theoretical studies of the concentration dependences of d–d transition band,g factors,and local distortion for V4+ in Li2O–PbO–B2O3–P2O5 glasses

In this work, the g factors, d–d transition band, local distortion, and their concentration dependences for impurity V⁴⁺ in 20Li₂O–20PbO–45B₂O₃–(15 − x)P₂O₅:V₂O₅ (0 ≤ x ≤ 2.5 mol%) glasses are theoretically investigated by using perturbation formulas of g factors for a tetragonally compressed octahedral 3d¹ cluster. In the light of the cubic polynomial concentration functions for cubic field parameter D_q, covalency factor N, and relative tetragonal compression ratio ρ, the calculated concentration dependences of d–d transition band and g factors for V⁴⁺ show good agreement with the experimental data. With increasing x, N (≈0.7682–0.8165) displays the monotonously increasing trend, whereas ρ (≈6.5–4.2%) and D_q (≈1504.9–1481.1 cm⁻¹) exhibit the decreasing tendencies. The above concentration dependences can be ascribed to the modifications of the V⁴⁺–O²⁻ bonding and orbital admixtures around the impurity V⁴⁺ due to the effects of V₂O₅ doping on the stability of the glass network, the strength of local crystal fields, and the electron cloud distribution.     

Rosmanol and Carnosol Synergistically Alleviate Rheumatoid Arthritis through Inhibiting TLR4/NF-κB/MAPK Pathway

Callicarpalongissima has been used as a Yao folk medicine to treat arthritis for years in China, although its active anti-arthritic moieties have not been clarified so far. In this study, two natural phenolic diterpenoids with anti-rheumatoid arthritis (RA) effects, rosmanol and carnosol, isolated from the medicinal plant were reported on for the first time. In type II collagen-induced arthritis DBA/1 mice, both rosmanol (40 mg/kg/d) and carnosol (40 mg/kg/d) alone alleviated the RA symptoms, such as swelling, redness, and synovitis; decreased the arthritis index score; and downregulated the serum pro-inflammatory cytokine levels of interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), and tumor necrosis factor α (TNF-α). Additionally, they blocked the activation of the Toll-like receptor 4 (TLR4)/nuclear factor κB (NF-κB)/c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways. Of particular interest was that when they were used in combination (20 mg/kg/d each), the anti-RA effect and inhibitory activity on the TLR4/NF-κB/MAPK pathway were significantly enhanced. The results demonstrated that rosmanol and carnosol synergistically alleviated RA by inhibiting inflammation through regulating the TLR4/NF-κB/MAPK pathway, meaning they have the potential to be developed into novel, safe natural combinations for the treatment of RA.     

Metabolomic-based investigation of Yinlan alleviating hyperlipidemia by inhibiting blood stasis and phlegm turbidity through the PXR-CYP3A4-ABCB1-FXR pathway

Yinlan lipid regulatory capsule (YL) is a composite traditional Chinese medicine (TCM) new drug to alleviate hyperlipidemia, while its therapeutic mechanism in vivo was not clarified with nontargeted metabolomics investigation. An animal model was established in rats fed a high-fat diet, and their body weights, body mass index (BMI) and blood cholesterol levels were measured. Serum, liver and kidney tissue samples were also extracted for PXR-CYP3A4-ABCB1-FXR signaling pathway research using PCR and UHPLC–MS. The obtained plasma samples were analyzed by UHPLC-Q-TOF-MS metabolomic investigation, which revealed PXR-CYP3A4-related metabolites and changes induced by YL. Finally, the key metabolites were chosen as index components, and their levels in the serum, liver, small intestine and bile were used for simultaneous UHPLC–MS-MS determination. The results indicated that YL was effective in rebalancing blood TG and TC levels (compared to controls). With respect to the PXR-CYP3A4-ABCB1 pathway, as a result of YL’s effect, gene expression or activity of the two targets decreased significantly in both the liver and kidney. The same trend was observed in the serum samples mentioned above. Metabolomics screening and data revealed that 44 metabolites can be regarded as biomarkers related to hyperlipidemia, fatty acids synthesis, and body energy consumption, as well as synthesis, transportation and exertion of cholesterol. YL’s treatment focused on 26 of them, primarily bile acids, indicating that the antihyperlipidemic effect of this drug lies in its inhibitory activity of cholesterol metabolism. Subsequent analysis of those in vivo components revealed that significant increases (compared to the model group) occurred in the blood, liver, small intestine and bile in groups that received medium and high doses of YL (while the low dose was relatively unchanged). Those target components exhibit a close relationship with PXR and/or CYP3A4. The use of YL repressed PXR expression and subsequently decreased CYP3A4 activity. As a result, synthesis of related bile acids increased, while cholesterol levels decreased, consequently leading to the attenuation of hyperlipidemia. This study comprehensively investigated the antihyperlipidemia mechanism of YL based on its repression of PXR-CYP3A4 activity and related metabolite yield, establishing an accurate method for evaluating the therapeutic effect of YL.     

Polymyxin B Combined with Minocycline: A Potentially Effective Combination against blaOXA-23-harboring CRAB in In Vitro PK/PD Model

Polymyxin-based combination therapy is commonly used to treat carbapenem-resistant Acinetobacter baumannii (CRAB) infections. In the present study, the bactericidal effect of polymyxin B and minocycline combination was tested in three CRAB strains containing bla_OXA-23 by the checkerboard assay and in vitro dynamic pharmacokinetics/pharmacodynamics (PK/PD) model. The combination showed synergistic or partial synergistic effect (fractional inhibitory concentration index ≤0.56) on the tested strains in checkboard assays. The antibacterial activity was enhanced in the combination group compared with either monotherapy in in vitro PK/PD model. The combination regimen (simultaneous infusion of 0.75 mg/kg polymyxin B and 100 mg minocycline via 2 h infusion) reduced bacterial colony counts by 0.9–3.5 log₁₀ colony forming units per milliliter (CFU/mL) compared with either drug alone at 24 h. In conclusion, 0.75 mg/kg polymyxin B combined with 100 mg minocycline via 2 h infusion could be a promising treatment option for CRAB bloodstream infections.